Having Ocugen shorted has been one of my finest deals deals this year.
I was lucky enough to stay short until now.
But now I think that it's time for a correction. Not long ago there was a lot of buying phantasy among analysts and dealers. They have been disappointed.
What is the situation now? I think that the market is almost clean now. Disappointed traders...
The previous week could not reach the high of the week before. This was a hint that the bullish momentum is slowing down. The price reaction this week has confirmed this bias as the attempt to reached this high again has been sold immediately.
This high seems to become an important resistance zone as it was a support zone for half a year from March to September...
OCGN has been a great swing trade after buying bad news. The good news has replaced the
bad. Earnings are in three days. Price well below ATH. November earnings were a beat
meaning this risky Med Tech penny stock had a lower cash burn than projected. Now
legal costs will disappear. Going long with a decent position expecting a better earnings.
In law, the...
The impressive correction 3 weeks ago of the little attempt to resume the long lasting decline since end 2020 is a signal that the market is still not convinced in a coming rebound of Ocugen.
We have just retraced the last branch of the downtrend which had lasted from July 2022 until the end of October 2023. Thus it may be a good time to find out the chances of...
My trading idea for - #Ocugen - BUY
Entry: 0.95 USD
Target: 8.00 USD (+720% profit)
Ocugen, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies to cure eye diseases. Its product pipeline candidates include OCU400, OCU410, OCU200, and COVAXIN. The firm's modifier gene therapy platform is engaged in addressing...
Looking at this channel on ocgn. perhaps a break might occur.
Disclaimer- this is only for educational purposes, its neither a buy or sell recommendation. past results is not a guarantee for future returns.
NASDAQ:OCGN Ocugen Inc
Long term PTs 16 - 21 - 180 and higher
Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on the developing gene therapies to cure blindness diseases. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited...
HUGE INVESTORS.
A fully integrated, patient-centric biotech company focused on vaccines in support of public health and gene and cell therapies
HUGE FUTURE POTENTIAL
The wyckoff method is a very accurate method, There are many variations and purposes--soley to liquidate others or take shares from retail or weak hands, To sell of shares to FOMO traders or breakout traders. Liquidating Other institutions or create misleading Bullish signals and prices to entice investors etc, etc. the real skill is identifying the purpose of...
Green is a parallel channel pattern @ daily time frame
BLue is a parallel channel pattern @ hourly time frame
Depending on your trading strategy/Time frame....it still follows the trend.
When we gonna break the 2.90 Resistance??
Ocugen is a biotechnology company focused on discovering, developing and commercializing novel gene therapies, biologicals and vaccines.
They announced yesterday that it will host a conference call to provide a business update and discuss its first quarter 2022 financial results tomorrow, May 6, before the market opens.
As soon as i saw the news, there were also...
Ocugen is still week but it shows small signs of reversal.
It can bounce from 2.20 to 2.40 in the coming week for a 10% gain.
1st target 2.40
2nd target 2.60
This is not an investment advice.
Looking for a pullback on Monday then a run up to the fib levels. Will it get a squeeze? Let's see. Closed over the 8 EMA and hoping for it to stay above it.
